Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 4/2004

01.04.2004 | Article

Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare Homes

verfasst von: I. Tinoco, J. A. Girón-González, M. T. González-González, A. Vergara de Campos, L. Rodríguez-Félix, A. Serrano, A. Bascuñana

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

With the objective of analyzing the efficacy of directly observed treatment (DOT) of HIV infection in the management of severely immunodepressed patients, this method was examined in individuals cared for in two social welfare facilities for HIV-infected persons and compared to self-administered therapy in outpatients. Forty-seven patients with registered HIV infection, stage C, were assigned to DOT for 9 months, the majority of whom had previously received antiretroviral therapy. A group of 51 HIV-infected outpatients, who attended day clinics attached to the reference hospitals, served as a comparison group. Together with increases in weight (9.2±7.5 kg) and Karnofsky scores (16.9±12.2) in the DOT group, a significant improvement of surrogate markers, such as CD4+ T-cell counts (increase in DOT group, 113.4±151.0 cells/µl; control group, −2.8±114.1 cells/µl; P<0.001) and HIV load (decrease in DOT group, −1.7±2.3 log10 copies/ml; control group, −0.4±1.5 log10 copies/ml; P<0.01) was detected in the DOT group. Morbidity and mortality were similar in both groups. The results indicate that such welfare facilities provide a useful framework not only for social objectives but also for healthcare purposes.
Literatur
1.
Zurück zum Zitat Stone VE (2001) Strategies for optimizing adherence to highly active anti-retroviral therapy: lessons from research and clinical practice. Clin Infect Dis 33:865–872CrossRefPubMed Stone VE (2001) Strategies for optimizing adherence to highly active anti-retroviral therapy: lessons from research and clinical practice. Clin Infect Dis 33:865–872CrossRefPubMed
2.
Zurück zum Zitat Woodward WC (1996) Should directly observed therapy be considered for treatment of HIV? JAMA 276:1956CrossRefPubMed Woodward WC (1996) Should directly observed therapy be considered for treatment of HIV? JAMA 276:1956CrossRefPubMed
3.
Zurück zum Zitat Sherer R (1998) Adherence and antiretroviral therapy in injection drug users. JAMA 280:567–568CrossRefPubMed Sherer R (1998) Adherence and antiretroviral therapy in injection drug users. JAMA 280:567–568CrossRefPubMed
4.
Zurück zum Zitat Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M (1998) Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 10:297–312PubMed Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M (1998) Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 10:297–312PubMed
5.
Zurück zum Zitat Mitty JA, Mckenzie M, Stenzel M, Flanigan T, Carpenter CCJ (1999) Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 282:1334CrossRefPubMed Mitty JA, Mckenzie M, Stenzel M, Flanigan T, Carpenter CCJ (1999) Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 282:1334CrossRefPubMed
6.
Zurück zum Zitat Chaulk CP, Kazandijian VA (1998) Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 279:943–948CrossRefPubMed Chaulk CP, Kazandijian VA (1998) Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 279:943–948CrossRefPubMed
7.
Zurück zum Zitat Babudiere S, Aceti A, D’Offizi GP, Carbonara S, Starnini G (2000) Directly observed therapy to treat HIV infection in prisoners. JAMA 284:179–180PubMed Babudiere S, Aceti A, D’Offizi GP, Carbonara S, Starnini G (2000) Directly observed therapy to treat HIV infection in prisoners. JAMA 284:179–180PubMed
8.
Zurück zum Zitat Lanzafame M, Trevenzoli M, Cattelan AM, Lazzarini L, Vento Ercole Concia S (2000) Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 25:200–201CrossRefPubMed Lanzafame M, Trevenzoli M, Cattelan AM, Lazzarini L, Vento Ercole Concia S (2000) Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 25:200–201CrossRefPubMed
9.
Zurück zum Zitat Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T (2002) Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 34:984–990CrossRefPubMed Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T (2002) Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 34:984–990CrossRefPubMed
10.
Zurück zum Zitat Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY (2001) Community-based approaches to HIV treatment in resource-poor setting. Lancet 358:404–409CrossRefPubMed Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY (2001) Community-based approaches to HIV treatment in resource-poor setting. Lancet 358:404–409CrossRefPubMed
11.
Zurück zum Zitat Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78–86CrossRefPubMed Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78–86CrossRefPubMed
12.
Zurück zum Zitat Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:2936–2937 Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:2936–2937
13.
Zurück zum Zitat McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–855 McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–855
14.
Zurück zum Zitat Centers for Diseases Control (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:RR-17 Centers for Diseases Control (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:RR-17
15.
Zurück zum Zitat Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A, GEEMA Study Group (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 16:605–613CrossRefPubMed Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A, GEEMA Study Group (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 16:605–613CrossRefPubMed
16.
Zurück zum Zitat López-Suárez A, Fernández-Gutiérrez del Álamo C, Pérez-Guzmán E, Girón-González JA (1998) Adherence to antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 12:685–686PubMed López-Suárez A, Fernández-Gutiérrez del Álamo C, Pérez-Guzmán E, Girón-González JA (1998) Adherence to antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 12:685–686PubMed
17.
Zurück zum Zitat Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35–43CrossRef Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35–43CrossRef
18.
Zurück zum Zitat Torre D, Tambini R (2002) Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 3:1–8PubMed Torre D, Tambini R (2002) Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 3:1–8PubMed
19.
Zurück zum Zitat Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study. JAMA 282:2220–2226CrossRefPubMed Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study. JAMA 282:2220–2226CrossRefPubMed
Metadaten
Titel
Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare Homes
verfasst von
I. Tinoco
J. A. Girón-González
M. T. González-González
A. Vergara de Campos
L. Rodríguez-Félix
A. Serrano
A. Bascuñana
Publikationsdatum
01.04.2004
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2004
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1099-8

Weitere Artikel der Ausgabe 4/2004

European Journal of Clinical Microbiology & Infectious Diseases 4/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.